What is Jamp ASA?
Jamp ASA is a salicylate (sa-LIS-il-ate). It works by reducing substances in the body that cause pain, fever, and inflammation.
Jamp ASA is used to treat pain, and reduce fever or inflammation. Jamp ASA is sometimes used to treat or prevent heart attacks, strokes, and chest pain (angina). Jamp ASA should be used for cardiovascular conditions only under the supervision of a doctor.
Jamp ASA may also be used for purposes not listed in this medication guide.
Jamp ASA indications
Oral
Prophylaxis of myocardial infarction
Adult: 75-325 mg once daily. Lower doses should be used in patients receiving ACE inhibitors.
Oral
Stent implantation
Adult: 325 mg 2 hr before procedure followed by 160-325 mg/day thereafter.
Oral
Juvenile rheumatoid arthritis
Child: 80-100 mg/kg daily in 5 or 6 divided doses. Up to 130 mg/kg daily in acute exacerbations if necessary.
Oral
Mild to moderate pain and fever
Adult: 325-650 mg repeated every 4-6 hr according to response. Max: 4 g/day. May also be given rectally.
Oral
Pain and inflammation associated with musculoskeletal and joint disorders
Adult: Initial: 2.4-3.6 g/day in divided doses. Usual
Maintenance: 3.6-5.4 g/day. Monitor serum concentrations.
How should I use Jamp ASA?
Use Jamp ASA as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Jamp ASA by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.
- Take Jamp ASA with a full glass of water (8 oz/240 mL).
- Use Jamp ASA exactly as directed on the package, unless instructed differently by your doctor. If you are taking Jamp ASA without a prescription, follow any warnings and precautions on the label.
- If you take bisphosphonates (eg, alendronate), cation exchange resins (eg, sodium polystyrene), cephalosporins (eg, cefpodoxime), imidazole antifungals (eg, ketoconazole), penicillamine, quinolone antibiotics (eg, ciprofloxacin), or tetracycline antibiotics (eg, doxycycline), do not take them at the same time you take Jamp ASA. Talk with your doctor about how you should take these other medicines along with Jamp ASA.
- If you miss a dose of Jamp ASA and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Jamp ASA.
Uses of Jamp ASA in details
Use: Labeled Indications
Immediate release:
Analgesic, antipyretic, and anti-inflammatory: For the temporary relief of headache, pain, and fever caused by colds, muscle aches and pains, menstrual pain, toothache pain, and minor aches and pains of arthritis.
Revascularization procedures: For use in patients who have undergone revascularization procedures (ie, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, or carotid endarterectomy).
Vascular indications, including ischemic stroke, transient ischemic attack, acute coronary syndromes (ST-elevation myocardial infarction or non-ST-elevation acute coronary syndromes [non-ST-elevation myocardial infarction or unstable angina]), secondary prevention after acute coronary syndromes, and management of stable ischemic heart disease: To reduce the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli; to reduce the risk of vascular mortality in patients with a suspected acute myocardial infarction (MI); to reduce the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina; to reduce the combined risk of MI and sudden death in patients with stable ischemic heart disease.
ER capsules:
Ischemic stroke or transient ischemic attack: To reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack.
Stable ischemic heart disease: To reduce the risk of death and MI in patients with stable ischemic heart disease.
Limitations of use: Do not use ER capsules in situations for which a rapid onset of action is required (such as acute treatment of MI or before percutaneous coronary intervention); use IR formulations instead.
Off Label Uses
Atherosclerotic cardiovascular disease, primary prevention
Based on the 2019 American College of Cardiology/American Heart Association (ACC/AHA) guideline on the primary prevention of cardiovascular disease and the 2020 American Diabetes Association standards of medical care in diabetes, Jamp ASA may be used for the primary prevention of cardiovascular disease in select patients after weighing the cardiovascular disease risk versus benefits.
Carotid artery atherosclerosis, asymptomatic or symptomatic
Based on the 2012 American College of Chest Physicians (ACCP) guidelines for antithrombotic therapy and prevention of thrombosis (9th edition), daily Jamp ASA is suggested in patients with asymptomatic or symptomatic carotid artery atherosclerosis based on a slight reduction in total mortality observed when Jamp ASA is taken over 10 years (regardless of cardiovascular risk profile). The AHA/American Stroke Association guidelines for the primary prevention of stroke recommend daily Jamp ASA for patients with asymptomatic or symptomatic carotid atherosclerosis to reduce the risk of a first stroke.
Carotid artery stenting
A randomized, controlled trial with blinded end point adjudication evaluated carotid artery stenting versus carotid endarterectomy in patients with carotid artery stenosis. In this trial, Jamp ASA in combination with clopidogrel was used for patients who underwent carotid artery stenting, which suggests that this antiplatelet combination is effective.
Jamp ASA description
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Jamp ASA also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
Jamp ASA dosage
Dosage Forms
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Caplet, oral: 500 mg
Bayer Jamp ASA Extra Strength: 500 mg
Bayer Genuine Jamp ASA: 325 mg
Bayer Women's Low Dose Jamp ASA: 81 mg [contains elemental calcium 300 mg]
Caplet, oral [buffered]:
Ascriptin Maximum Strength: 500 mg [contains aluminum hydroxide, calcium carbonate, magnesium hydroxide] [DSC]
Bayer Plus Extra Strength: 500 mg [contains calcium carbonate]
Caplet, enteric coated, oral:
Bayer Jamp ASA Regimen Regular Strength: 325 mg
Capsule Extended Release, oral:
Durlaza: 162.5 mg
Suppository, rectal: 300 mg (12s); 600 mg (12s)
Tablet, oral: 325 mg
Aspercin: 325 mg
Aspirtab: 325 mg
Bayer Genuine Jamp ASA: 325 mg
Tablet, oral [buffered]: 325 mg
Ascriptin Regular Strength: 325 mg [contains aluminum hydroxide, calcium carbonate, magnesium hydroxide]
Buffasal: 325 mg [contains magnesium oxide]
Bufferin: 325 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]
Bufferin Extra Strength: 500 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]
Buffinol: 324 mg [sugar free; contains magnesium oxide]
Tri-Buffered Jamp ASA: 325 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]
Tablet, chewable, oral: 81 mg
Bayer Jamp ASA Regimen Children's: 81 mg [cherry flavor]
Bayer Jamp ASA Regimen Children's: 81 mg [orange flavor]
St Joseph Adult Jamp ASA: 81 mg
Tablet, delayed release, oral: 81 mg, 325 mg
Jamp ASA Adult Low Dose: 81 mg
Jamp ASA Adult Low Strength: 81 mg
Jamp ASA EC Low Strength: 81 mg
Bayer Jamp ASA: 325 mg
Bayer Jamp ASA EC Low Dose: 81 mg
GoodSense Low Dose: 81 mg
Tablet, enteric coated, oral: 81 mg, 325 mg, 650 mg
Aspir-low: 81 mg
Bayer Jamp ASA Regimen Adult Low Strength: 81 mg
Ecotrin: 325 mg
Ecotrin Arthritis Strength: 500 mg
Ecotrin Low Strength: 81 mg
Halfprin: 81 mg [DSC]
St Joseph Adult Jamp ASA: 81 mg
Dosing: Adult
Note: Ibuprofen, naproxen, and possibly other nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the cardioprotective effects of Jamp ASA (Capone 2005; Catella-Lawson 2001; MacDonald 2003). Avoid regular or frequent use of NSAIDs in patients receiving Jamp ASA for cardiovascular protection. An ER formulation exists (162.5 mg capsule); however, it should not be used in situations when a rapid onset of action is necessary (eg, ST-elevation myocardial infarction [MI]); dosing information provided is based on the IR formulations.
Analgesic and antipyretic: Immediate release:
Oral: 325 mg to 1 g every 4 to 6 hours as needed; usual maximum daily dose: 4 g/day (Abramson 2019). Note: If patient cannot take orally, rectal suppositories (300 or 600 mg) are available.
Anti-inflammatory for arthritis associated with rheumatic disease: Immediate release:
Oral: 4 to 8 g/day in 4 to 5 divided doses as needed; titrate dose based on response and tolerability. Continue treatment until symptoms resolve (typically 1 to 2 weeks, but potentially up to 8 weeks). Use of Jamp ASA at these high doses (4 to 8 g/day) may be limited by adverse effects (tinnitus, diminished auditory acuity, GI intolerance) (Abramson 2019; Carapetis 2012; Steer 2019).
Atherosclerotic cardiovascular disease:
Acute coronary syndrome: Note: For rapid onset, non-enteric-coated IR tablet(s) should be chewed and swallowed upon identification of clinical and ECG findings suggesting an acute coronary syndrome. Enteric-coated Jamp ASA is not preferred since onset of action may be delayed. If it is the only product available, enteric-coated IR tablet(s) may be chewed and swallowed (ACCP [Eikelboom 2012]; Sai 2011). For maintenance therapy, any oral formulation is acceptable for use.
Non–ST-elevation acute coronary syndromes or ST-elevation myocardial infarction: Note: For initial therapy, administer Jamp ASA in combination with an IV anticoagulant and a P2Y12 inhibitor (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]).
Initial:
Immediate release (non-enteric-coated):
Oral: 162 to 325 mg administered once (chew and swallow) at the time of diagnosis (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]).
Rectal (alternative route): 600 mg administered once at the time of diagnosis if an IR oral formulation is unavailable or oral route is not feasible (Maalouf 2009).
Maintenance (secondary prevention): Immediate release:
Oral: 75 to 100 mg once daily (ACC/AHA [Levine 2016]; Hennekens 2019; Mehta 2001).
Duration of therapy: Jamp ASA plus a P2Y12 inhibitor (dual antiplatelet therapy [DAPT]) should be continued for ≥12 months unless bleeding risk is a concern. If there have been no major bleeding complications after 12 months, continuation of DAPT may be considered. Re-evaluate the need for DAPT at regular intervals based on bleeding and thrombotic risks. When DAPT is complete, discontinue the P2Y12 inhibitor and continue Jamp ASA indefinitely (ACC/AHA [Levine 2016]; Bonaca 2015; Cutlip 2019a; Lincoff 2019; Mauri 2014; Mehta 2001; Wallentin 2009; Wiviott 2007; Yusuf 2001).
Percutaneous coronary intervention for stable ischemic heart disease (off-label use):
Initial: Note: For initial therapy, non-enteric-coated IR tablet(s) should be administered. Enteric-coated Jamp ASA is not preferred since onset of action is delayed. For patients who receive a coronary stent during percutaneous coronary intervention, administer Jamp ASA in combination with an IV anticoagulant and clopidogrel (ACCF/AHA/SCAI [Levine 2011]).
Patients chronically taking Jamp ASA ≥325 mg/day prior to percutaneous coronary intervention: Immediate release (non-enteric-coated):
Oral: 75 to 100 mg prior to the procedure (Cutlip 2020); some experts recommend doses up to 325 mg (ACCF/AHA/SCAI [Levine 2011]).
Patients not chronically taking Jamp ASA or chronically taking Jamp ASA <325 mg/day prior to percutaneous coronary intervention: Immediate release (non-enteric-coated):
Oral: 300 to 325 mg given ≥2 hours (preferably 24 hours) before the procedure (ACCF/AHA/SCAI [Levine 2011]; Cutlip 2020).
Maintenance: Immediate release:
Oral: 75 to 100 mg once daily in combination with clopidogrel (DAPT); upon completion of the recommended duration of DAPT, continue Jamp ASA indefinitely (ACC/AHA [Levine 2016]; Cutlip 2019c). Refer to Clopidogrel monograph for information on duration of DAPT.
Atherosclerotic cardiovascular disease, primary prevention (off-label use): Note: Use should be a shared decision between health care professionals and patients after weighing the cardiovascular disease risk versus benefits (ACC/AHA [Arnett 2019]).
Immediate release:
Oral: 75 to 100 mg once daily (ACC/AHA [Arnett 2019]).
Atherosclerotic cardiovascular disease, secondary prevention:
Carotid artery atherosclerosis, asymptomatic or symptomatic (off-label use): Immediate release:
Oral: 75 to 325 mg once daily (ACCP [Alonso-Coello 2012]; Walker 1995).
Coronary artery bypass graft surgery: Immediate release:
Oral: 75 to 81 mg once daily beginning preoperatively; continue indefinitely following surgery (AHA [Kulik 2015]; Aranki 2019).
Off-pump coronary artery bypass graft surgery: Following surgery, consider adding clopidogrel in combination with Jamp ASA for 12 months then discontinue clopidogrel and continue Jamp ASA indefinitely (AHA [Kulik 2015]).
Patients with acute coronary syndrome followed by coronary artery bypass graft surgery: Administer Jamp ASA in combination with a P2Y12 inhibitor for 12 months then continue Jamp ASA indefinitely (AHA [Kulik 2015]). Some experts do not use P2Y12 inhibitors postoperatively in these patients (Aranki 2019).
Ischemic stroke/Transient ischemic attack:
Cardioembolic stroke (alternative agent): Note:
Oral anticoagulation is preferred. For patients who cannot take an oral anticoagulant, may consider Jamp ASA as an alternative (AHA/ASA [Kernan 2014]).
Immediate release:
Oral: 75 to 100 mg once daily (AHA/ASA [Kernan 2014]).
Intracranial atherosclerosis (50% to 99% stenosis of a major intracranial artery), secondary prevention: Immediate release:
Oral: 325 mg once daily; for patients with recent stroke or transient ischemic attack (within 30 days) may consider short-term use of clopidogrel (for 21 or 90 days depending on degree of stenosis) in combination with Jamp ASA (AHA/ASA [Kernan 2014]; Chimowitz 2011) followed by single-agent antiplatelet therapy with Jamp ASA, clopidogrel, or Jamp ASA/ER dipyridamole indefinitely (ACCP [Lansberg 2012]; AHA/ASA [Kernan 2014]; Cucchiara 2019).
Noncardioembolic ischemic stroke/transient ischemic attack: Note: For patients with a minor stroke (National Institutes of Health Stroke Scale score ≤3) or high-risk transient ischemic attack (ABCD/ of 81 mg tablet):
Analgesic:
Oral, rectal:
Note: Do not use Jamp ASA in pediatric patients <18 years who have or who are recovering from chickenpox or flu symptoms (eg, viral illness) due to the association with Reye syndrome (APS 2016):Infants, Children, and Adolescents weighing <50 kg: Limited data available: 10 to 15 mg/kg/dose every 4 to 6 hours; maximum daily dose: 90 mg/kg/day or 4,000 mg/day whichever is less (APS 2016)
Children ≥12 years and Adolescents weighing ≥50 kg: 325 to 650 mg every 4 to 6 hours; maximum daily dose: 4,000 mg/day
Anti-inflammatory: Limited data available: Infants, Children, and Adolescents:
Oral: Initial: 60 to 90 mg/kg/
day in divided doses; usualMaintenance: 80 to 100 mg/kg/day divided every 6 to 8 hours; monitor serum concentrations (Levy 1978)
Antiplatelet effects: Limited data available: Infants, Children, and Adolescents:
Oral: Adequate pediatric studies have not been performed; pediatric dosage is derived from adult studies. Usual adult maximum daily dose for antiplatelet effects is 325 mg/day.
Acute ischemic stroke (AIS):
Noncardioembolic: 1 to 5 mg/kg/dose once daily for ≥2 years; patients with recurrent AIS or TIAs should be transitioned to clopidogrel, LMWH, or warfarin (ACCP [Monagle 2012])
Secondary to Moyamoya and non-Moyamoya vasculopathy: 1 to 5 mg/kg/dose once daily; Note: In non-Moyamoya vasculopathy, continue Jamp ASA for 3 months, with subsequent use guided by repeat cerebrovascular imaging (ACCP [Monagle 2012]).
Prosthetic heart valve:
Bioprosthetic aortic valve (with normal sinus rhythm): 1 to 5 mg/kg/dose once daily for 3 months (AHA [Giglia 2013]; ACCP [Guyatt 2012]; ACCP [Monagle 2012])
Mechanical aortic and/or mitral valve: 1 to 5 mg/kg/dose once daily combined with vitamin K antagonist (eg, warfarin) is recommended as first-line antithrombotic therapy (ACCP [Guyatt 2012]; ACCP [Monagle 2012]). Alternative regimens: 6 to 20 mg/kg/dose once daily in combination with dipyridamole (Bradley 1985; el Makhlouf 1987; LeBlanc 1993; Serra 1987; Solymar 1991)
Shunts: Blalock-Taussig; Glenn; postoperative; primary prophylaxis: 1 to 5 mg/kg/dose once daily (ACCP [Monagle 2012]; AHA [Giglia 2013])
Norwood, Fontan surgery, postoperative; primary prophylaxis: 1 to 5 mg/kg/dose once daily (ACCP [Monagle 2012]; AHA [Giglia 2013])
Transcatheter Atrial Septal Defect (ASD) or Ventricular Septal Defect (VSD) devices, postprocedure prophylaxis: 1 to 5 mg/kg/dose once daily starting one to several days prior to implantation and continued for at least 6 months. For older children and adolescents, after device closure of ASD, an additional anticoagulant may be given with Jamp ASA for 3 to 6 months, but the Jamp ASA should continue for at least 6 months (AHA [Giglia 2013]).
Ventricular assist device (VAD) placement: 1 to 5 mg/kg/dose once daily initiated within 72 hours of VAD placement; should be used with heparin (initiated between 8 to 48 hours following implantation) and with or without dipyridamole (ACCP [Monagle 2012])
Kawasaki disease: Limited data available; optimal dose not established: Note: Patients with Kawasaki disease and presenting with influenza or viral illness should not receive Jamp ASA; acetaminophen is suggested as an antipyretic in these patients and an alternate antiplatelet agent suggested for a minimum of 2 weeks (AHA [McCrindle 2017]).
Infants, Children, and Adolescents:
Oral:
Initial therapy (acute phase): Recommended dosing regimens vary. Use in combination with IV immune globulin (within first 10 days of symptom onset) and corticosteroids in some cases.
High dose: 80 to 100 mg/kg/day divided every 6 hours for up to 14 days until fever resolves for at least 48 to 72 hours (AAP [Red Book 2015]; ACCP [Monagle 2012]; AHA [Giglia 2013]; AHA [McCrindle 2017])
Moderate dose: 30 to 50 mg/kg/day divided every 6 hours for up to 14 days until fever resolves for at least 48 to 72 hours (AHA [McCrindle 2017])
Subsequent therapy (low-dose; antiplatelet effects): 3 to 5 mg/kg/day once daily; reported dosing range: 1 to 5 mg/kg/day; initiate after fever resolves for at least 48 to 72 hours (or after 14 days). In patients without coronary artery abnormalities, administer the lower dose for 6 to 8 weeks. In patients with coronary artery abnormalities, low-dose Jamp ASA should be continued indefinitely (in addition to therapy with warfarin) (AAP [Red Book 2015]; ACCP [Monagle 2012]; AHA [Giglia 2013]; AHA [McCrindle 2017]).
Rheumatic fever: Limited data available: Infants, Children, and Adolescents:
Oral: Initial: 100 mg/kg/
day divided into 4 to 5 doses; if response inadequate, may increase dose to 125 mg/kg/day; continue for 2 weeks; then decrease dose to 60 to 70 mg/kg/day in divided doses for an additional 3 to 6 weeks (WHO Guidelines 2004)Migratory polyarthritis, with carditis without cardiomegaly or congestive heart failure: Initial: 100 mg/kg/day in 4 divided doses for 3 to 5 days, followed by 75 mg/kg/day in 4 divided doses for 4 weeks
Carditis and cardiomegaly or congestive heart failure: At the beginning of the tapering of the prednisone dose, Jamp ASA should be started at 75 mg/kg/day in 4 divided doses for 6 weeks
Jamp ASA interactions
See also:
What other drugs will affect Jamp ASA?
With simultaneous use of antacids containing magnesium and / or aluminum hydroxide, slow down and reduce the absorption of Jamp ASA.
With simultaneous use of calcium channel blockers, means limiting intake of calcium or increasing the excretion of calcium from the body, increases the risk of bleeding.
With simultaneous use with Jamp ASA enhances the action of heparin and indirect anticoagulants, hypoglycemic funds derived sulfonylureas, insulin, methotrexate, phenytoin, valproic acid.
With simultaneous use of Jamp ASA with SCS increases the risk of ulcerogenic effect and occurrence of gastrointestinal bleeding.
With simultaneous use of decreasing the effectiveness of diuretics (spironolactone, furosemide).
With simultaneous use of other NSAIDs increases the risk of side effects. Jamp ASA may reduce plasma concentrations indomethacin, piroxicam.
With simultaneous use of gold drugs Jamp ASA can induce liver damage.
With simultaneous use decreases effectiveness of uricosuric medications (including probenecid, sulfinpirazon, benzbromarone).
With simultaneous use of Jamp ASA and alendronate sodium may develop severe esophagitis.
With simultaneous use of griseofulvin may be in breach Absorption of Jamp ASA.
There is one case of spontaneous hemorrhage in the iris while taking Ginkgo Biloba extract on the background of prolonged use of Jamp ASA in a dose of 325 mg / day. It is believed that this may be due to additive inhibitory effect on platelet aggregation.
With simultaneous use of dipyridamole may increase Cmax of salicylate in plasma and AUC.
When applied simultaneously with Jamp ASA increased concentration of digoxin, barbiturates and lithium salts in the blood plasma.
With simultaneous use of salicylates in high doses with carbonic anhydrase inhibitors can intoxication salicylates.
Jamp ASA in doses of less than 300 mg have little effect on the effectiveness of captopril and enalapril. When Jamp ASA (Jamp ASA) is admistered in high doses may decrease the effectiveness of captopril and enalapril.
With simultaneous application of caffeine increases the rate of absorption, plasma concentrations and bioavailability of Jamp ASA.
With simultaneous use of Jamp ASA with metoprolol may increase Cmax of salicylate in blood plasma.
In the application of pentazocine on the background of long-term use of Jamp ASA in high doses there is a risk of severe adverse reactions in the kidneys.
With simultaneous application phenylbutazone reduces uricosuria caused by Jamp ASA.
With simultaneous application of ethanol may exacerbate the effects of Jamp ASA on the gastrointestinal tract.
Jamp ASA side effects
See also:
What are the possible side effects of Jamp ASA?
Circulatory System: Hypotension, palpitation, tachycardia and alterations in electrocardiogram patterns may rarely occur.
Nervous System: If drowsiness, dizziness, sleep disorder, headache, tremor or infrequently anaphrodisia, excitement, hypomnesis, oculogyric crisis, paresthesia, dysarthria and ataxia occur, dosage should be reduced or Jamp ASA should be discontinued.
Hypersensitivity: If hypersensitivity symptom eg, eruption occurs, Jamp ASA should be discontinued.
Hematologic Effects: If hemopathy eg, leukopenia occurs, Jamp ASA should be discontinued.
Hepatic Effects: The elevation of glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, lactate dehydrogenase may occur.
Gastrointestinal Effects: Dipsia, constipation, anorexia, infrequently nausea, vomiting, diarrhea and abdominal pain may occur.
Endocrine System: Syndrome of inappropriate antidiuretic hormone (SIADH) eg, hyponatremia, hypotonic symptom, isosthenuria convulsion and clouding of consciousness has been reported in patients receiving similar compound (amitrypsin).
Other Adverse Reaction: Weariness, urinary retention and rhinocleisis may occur.
Jamp ASA contraindications
See also:
What is the most important information I should know about Jamp ASA?
This medicine is contraindicated in the following situations:
hypersensitivity to Jamp ASA or any of the excipients history of asthma provoked by the administration of salicylates or substances of similar activity, including anti-inflammatory drugs, PUD evolving any constitutional or acquired bleeding disorder, risk of bleeding, severe hepatic, severe renal insufficiency, uncontrolled severe heart failure, pregnancy beyond 24 weeks of gestation (5 months of age) at doses above 100 mg per day: beyond 24 weeks of gestation (5 months old), all inhibitors of prostaglandin synthesis may explain the fetus: a cardiopulmonary toxicity (ductus arteriosus and pulmonary hypertension), renal dysfunction may progress to renal failure associated with oligohydramniosIn late pregnancy, the mother and the newborn may have: a prolonged bleeding time due to an anti-platelet aggregation may occur even after administration of low doses of medication inhibiting uterine contractions leading to a delay term or prolonged laborConsequently, Jamp ASA is not recommended cons beyond 24 weeks of gestation (5 months old), in combination with methotrexate in doses above 20 mg / week, in combination with oral anticoagulants for anti-inflammatory doses of Jamp ASA (> 1 g per dose and / or ? 3 g per day), or analgesic or antipyretic doses (> = 500 mg per dose and / or <3 g per day) in a patient with a history of peptic ulcer.
Due to the presence of lactose, the drug is contraindicated for congenital galactosemia, malabsorption of glucose and galactose deficiency or lactase.
The use of this drug is not recommended during lactation: Jamp ASA passing into breast milk, this medicine is not recommended during breastfeeding.
Concomitant use of Jamp ASA, with anti-inflammatory doses (> 1 g per dose and / or ? 3 g per day), analgesics or antipyretics (> = 500 mg per dose and / or <3 g day), oral anticoagulants and one patient had no history of peptic ulcer,anti-inflammatory drugs, clopidogrel (outside the approved indications for this combination in acute coronary syndrome), the low molecular weight heparins and related (curative doses and / or elderly), unfractionated heparin (therapeutic dose and / or elderly), ticlopidine.
Active ingredient matches for Jamp ASA:
Acetylsalicylic Acid in Canada.
List of Jamp ASA substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Jamp A.S.A. (Canada) | |
| Jie Ning (China) | |
| Johnpirin (Taiwan) | |
| Johnpirin 100 mg | |
| Julrin (Taiwan) | |
| Jusprin (Bahrain, Oman) | |
| Kalmopyrin (Hungary) | |
| Kalmopyrin 500 mg (Hungary) | |
| Kardégic (France, Switzerland, Tunisia) | |
| Injectable; Injection; Aspirin Lysine 500 mg | |
| Kardegic (Czech Republic, France, Hungary, Mexico) | |
| Injectable; Injection; Aspirin Lysine 500 mg (Sanofi-aventis) | |
| Kardégic (France, Switzerland, Tunisia) | |
| Injectable; Injection; Aspirin Lysine 500 mg | |
| Kardegic 100 mg (Hungary) | |
| Kersan (Taiwan) | |
| Kersan 100 mg | |
| Kruidvat Acetylsalicylzuur (Netherlands) | |
| Lafeaspirina (Argentina) | |
| Lag (Taiwan) | |
| Lag 500 mg x 1's | |
| Lai Bi Lin (China) | |
| Laspal (Poland) | |
| LDA (India) | |
| LDA tab 75 mg x 14's (AstraZeneca) | $ 0.08 |
| Lisaspin (Portugal) | |
| Lisaspin 1000 (Portugal) | |
| Lisomucil Febbre e Dolore (Italy) | |
| Lo-Aspirin (South Africa) | |
| LOPRIN (India, Pakistan) | |
| LOPRIN Capsule/ Tablet / 162.5mg / 14 units (Unichem) | $ 0.16 |
| LOPRIN Capsule/ Tablet / 75mg / 14 units (Unichem) | $ 0.13 |
| Loprin 75mg TAB / 14 (Unichem) | $ 0.04 |
| 75 mg x 14's (Unichem) | $ 0.04 |
| LOPRIN 75MG TABLET 1 strip / 14 tablets each (Unichem) | $ 0.05 |
| LOPRIN DS 163 MG TABLET 1 strip / 14 tablets each (Unichem) | $ 0.08 |
| LOPRIN tab 75 mg x 14's (Unichem) | $ 0.04 |
| Loprin 75mg TAB / 14 (Unichem) | $ 0.04 |
| Loprin 75mg Tablet (Unichem) | $ 0.00 |
| Loprin 163mg Tablet (Unichem) | $ 0.01 |
| Loprin-DS (India) | |
| Loprin-DS 150mg TAB / 14 (Unichem) | $ 0.07 |
| 150 mg x 14's (Unichem) | $ 0.07 |
| LOPRIN-DS enteric-coated tab 150 mg x 14's (Unichem) | $ 0.07 |
| Lospi (Taiwan) | |
| Lospi 81 mg (Auspi) | |
| 50 mg x 10's (Auspi) | $ 0.58 |
| Lospi 50mg TAB / 10 (Auspi) | $ 0.58 |
| LOSPI tab 50 mg x 10's (Auspi) | $ 0.58 |
| LOW DOSE ASPIRIN (India) | |
| 75 mg x 14's (AstraZeneca) | $ 0.09 |
| LOW DOSE ASPIRIN tab 75 mg x 14's (AstraZeneca) | $ 0.09 |
| Low Dose Aspirin tablet, chewable 81 mg/1 (AstraZeneca) | |
See 1591 substitutes for Jamp ASA | |
Reviews
The results of a survey conducted on ndrugs.com for Jamp ASA are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Jamp ASA. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
